Hubert Landers, MD
Internal Medicine · Fort Smith, ARNPI 1538189634
Payments from drug & device makers
Across 427 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amarin Pharma, Inc.$780
- Merck$764
- Amgen$685
- Johnson & Johnson$560
- Bayer$501
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,63895%
- Education$3135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 78 | $1,240 |
| Amarin Pharma, Inc. | 45 | $780 |
| Merck | 46 | $764 |
| Amgen | 43 | $685 |
| Johnson & Johnson | 37 | $560 |
| Bayer | 33 | $501 |
| Astellas Pharma US Inc | 6 | $349 |
| AstraZeneca | 22 | $329 |
| Boehringer Ingelheim | 19 | $286 |
| AbbVie(2 entities) | 20 | $261 |
| Sanofi-aventis U.S. LLC | 8 | $137 |
| Esperion Therapeutics, Inc. | 10 | $136 |
| Regeneron Healthcare Solutions, Inc. | 7 | $109 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Eisai Inc. | 5 | $79 |
| Medtronic | 4 | $75 |
| Pfizer | 5 | $75 |
| Sunovion Pharmaceuticals Inc. | 5 | $48 |
| Lilly USA, LLC | 3 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $44 |
| Boston Scientific | 2 | $42 |
| Lundbeck LLC | 2 | $41 |
| Abbott | 2 | $35 |
| Exact Sciences | 2 | $34 |
| GSK | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Gilead | 2 | $23 |
| Abiomed | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
How this compares
$6,951 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 213 | $190,442 |
| JardianceEmpagliflozin | 93 | $75,888 |
| FarxigaDapagliflozin Propanediol | 77 | $72,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $64,152 |
| JanuviaSitagliptin Phosphate | 61 | $55,204 |
| EntrestoSacubitril/Valsartan | 61 | $49,713 |
| XareltoRivaroxaban | 51 | $41,987 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $22,531 |
| OzempicSemaglutide | 12 | $19,499 |
| MyrbetriqMirabegron | 34 | $16,657 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $16,608 |
| VraylarCariprazine Hcl | 11 | $16,136 |
| LinzessLinaclotide | 20 | $14,902 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,043 |
| SynthroidLevothyroxine Sodium | 93 | $7,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $75 | $195,950237 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $30 | $76,195107 claims |
| Boehringer IngelheimJardiance | $286 | $75,88893 claims |
| AstraZenecaFarxiga | $329 | $72,41077 claims |
| MerckJanuvia | $764 | $55,20461 claims |
| NovartisEntresto | $1,240 | $49,71361 claims |
| Johnson & JohnsonXarelto | $560 | $41,98751 claims |
| AbbVieVraylar, Linzess, Synthroid | $261 | $38,041124 claims |
| Novo NordiskOzempic | $12 | $19,49912 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $16,65734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Fort Smith
- Tyree SealsFort Smith$14K
- Brent ReevesFort Smith$6K
- Beena SyedFort Smith$6K
- Kendall WagnerFort Smith$6K
- Sumer PhillipsFort Smith$6K
- Becky YarboroughFort Smith$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.